Atlanta, GA – Scibility Media – 11/07/2014.
This article discusses two companies: Uranium Energy Corp.(NYSEMKT:UEC)and NxStage Medical, Inc.(NASDAQ:NXTM)
Uranium Energy Corp.(NYSEMKT:UEC) is a Texas-based industrial metals and minerals company that explores, extracts, and processes uranium concentrates on projects in the United States and the Republic of Paraguay. The company’s mineral rights include uranium projects in the following states: Arizona, Colorado, New Mexico, Texas, and Wyoming.
The company provided a recap of its operations and its financial results for the 2014 fiscal year on Oct. 14th, 2014. Uranium Energy’s highlights included a $20,000,000 senior secured credit facility that was dated and effective on Mar. 13th, 2014. The company had a trading volume of 3.34 million yesterday. This figure is more than six times higher than its three month average volume of 540,938.
NxStage Medical, Inc.(NASDAQ:NXTM) reported its third quarter financial results on Nov. 6th, 2014. The figures included a revenue of $75.3 million for the period, a 13% increase from the number recorded during the same period of the previous fiscal year. Additionally, NxStage also raised its full-year 2014 revenue guidance to $296-298 million.
The company traded for as much as $17.25 on Nov. 6th, 2014, a figure which represents a new 52 week low for NxStage Medical. Additionally, like Uranium Energy Corp., the company also saw its trading volume spike to a high mark. While the company has a three month average volume of 0.31 million, NxStage had a volume of 2.63 million on Nov. 6th.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to email@example.com and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.